Company intelligence / Profile preview
Galimedix Therapeutics
Kensington, Maryland, United Statesgalimedix.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Galimedix has demonstrated excellent safety and tolerability of its lead compound GAL‑101 as an eyedrop in early clinical testing. Preclinical models show efficacy against toxic Aβ species implicated in neurodegenerative diseases. The company’s topical GAL‑101 program for dry AMD will enter a pivotal Phase 2 trial (“DREAM” study) in late 2024. Oral GAL‑101 has entered Phase 1 to assess safety, PK, and blood-brain barrier penetration with future plans for Alzheimer’s disease trials. Both formulations aim to provide convenient administration with fewer side effects than current options.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small molecules (amyloid beta aggregation modulators)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Théa Open Innovation (TOI), supporting the upcoming pivotal trial of GAL‑101 eyedrops in dry AMD
Beyond the preview
Go deeper on Galimedix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galimedix Therapeutics.